Boston Scientific financials
$43.88−0.52%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.44B | $5.20B | $5.29B | $5.07B | $5.06B | $4.66B | $4.56B | $4.21B | $4.12B | $3.86B | $3.73B | $3.53B |
| Gross profit | $3.85B | $3.61B | $3.68B | $3.54B | $3.42B | $3.21B | $3.10B | $2.90B | $2.85B | $2.65B | $2.58B | $2.43B |
| Gross margin | 70.7% | 69.4% | 69.6% | 69.9% | 67.7% | 68.8% | 67.9% | 68.8% | 69.2% | 68.7% | 69.2% | 68.8% |
| Operating income | $1.18B | $1.10B | $825.0M | $1.05B | $819.0M | $921.0M | $675.0M | $733.0M | $520.0M | $675.0M | $584.0M | $693.0M |
| Net income | $907.0M | $1.34B | $672.0M | $755.0M | $797.0M | $674.0M | $565.0M | $469.0M | $324.0M | $495.0M | $505.0M | $505.0M |
| Net margin | 16.7% | 25.8% | 12.7% | 14.9% | 15.7% | 14.5% | 12.4% | 11.1% | 7.9% | 12.8% | 13.6% | 14.3% |
| Diluted EPS | $0.61 | $0.90 | $0.45 | $0.51 | $0.53 | $0.45 | $0.38 | $0.32 | $0.22 | $0.33 | $0.34 | $0.34 |
| EBITDA | $1.62B | $1.43B | $1.53B | $1.38B | $1.32B | $1.34B | $1.19B | $1.05B | $1.11B | $982.0M | $617.0M | $910.0M |
| Operating cash flow | $1.47B | $348.0M | $1.36B | $1.34B | $1.29B | $541.0M | $1.46B | $1.00B | $812.0M | $164.0M | $958.0M | $729.0M |
| Free cash flow | $1.28B | $171.0M | $1.01B | $1.16B | $1.13B | $354.0M | $1.18B | $824.0M | $657.0M | -$15.0M | $691.0M | $539.0M |
| Diluted shares | 1,474.8M | 1,495.0M | 1,495.9M | 1,495.5M | 1,493.5M | 1,493.1M | 1,490.3M | 1,487.4M | 1,484.2M | 1,481.7M | 1,476.8M | 1,475.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $539.0M | $1.45B | $1.97B | $1.27B | $534.0M | $725.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $12.62B | $11.03B | $11.44B | $11.60B | $11.59B | $11.31B |
| Total assets | $45.22B | $44.35B | $43.67B | $42.71B | $41.56B | $40.14B |
| Total liabilities | $20.04B | $18.25B | $19.20B | $19.08B | $18.91B | $17.70B |
| Shareholders' equity | $25.17B | $26.10B | $24.47B | $23.63B | $22.65B | $22.45B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology